95% CI, 0.630.85), with no significant interaction by sex ( Regarding safety, women experienced a higher incidence of genital infections while on SGLT-2 inhibitors, likely due to anatomical predisposition, which may impact treatment adherence ( For GLP-1 receptor agonists, the REWIND trial demonstrated a reduction in cardiovascular events with dulaglutide, with a trend toward greater benefit in women, although statistical significance was not achieved (RR 0.85
A metabolic-support approach may be discussed when concerns include insulin resistance, reduced exercise tolerance, fatigue, or poor metabolic flexibility
[PMID: 24587332] PubMed record related to this compound for laboratory literature review
Akita hold the patents on ssPalm chemicals
gykr), bromelain (1000 GDU/g), Q10 koenzim, borsmenta por ( Mentha x piperita